Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features

R. Maruyama, Shinichi Toyooka, K. O. Toyooka, K. Harada, A. K. Virmani, S. Zöchbauer-Müller, A. J. Farinas, F. Vakar-Lopez, J. D. Minna, A. Sagalowsky, B. Czerniak, A. F. Gazdar

Research output: Contribution to journalArticle

313 Citations (Scopus)

Abstract

We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARβ, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.

Original languageEnglish
Pages (from-to)8659-8663
Number of pages5
JournalCancer Research
Volume61
Issue number24
Publication statusPublished - Dec 15 2001
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Methylation
Genes
Ploidies
Gene Frequency
Neoplasms
Multivariate Analysis
Biomarkers
Muscles
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zöchbauer-Müller, S., ... Gazdar, A. F. (2001). Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Research, 61(24), 8659-8663.

Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. / Maruyama, R.; Toyooka, Shinichi; Toyooka, K. O.; Harada, K.; Virmani, A. K.; Zöchbauer-Müller, S.; Farinas, A. J.; Vakar-Lopez, F.; Minna, J. D.; Sagalowsky, A.; Czerniak, B.; Gazdar, A. F.

In: Cancer Research, Vol. 61, No. 24, 15.12.2001, p. 8659-8663.

Research output: Contribution to journalArticle

Maruyama, R, Toyooka, S, Toyooka, KO, Harada, K, Virmani, AK, Zöchbauer-Müller, S, Farinas, AJ, Vakar-Lopez, F, Minna, JD, Sagalowsky, A, Czerniak, B & Gazdar, AF 2001, 'Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features', Cancer Research, vol. 61, no. 24, pp. 8659-8663.
Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Research. 2001 Dec 15;61(24):8659-8663.
Maruyama, R. ; Toyooka, Shinichi ; Toyooka, K. O. ; Harada, K. ; Virmani, A. K. ; Zöchbauer-Müller, S. ; Farinas, A. J. ; Vakar-Lopez, F. ; Minna, J. D. ; Sagalowsky, A. ; Czerniak, B. ; Gazdar, A. F. / Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. In: Cancer Research. 2001 ; Vol. 61, No. 24. pp. 8659-8663.
@article{452b188e634c41ecb00bba06cdc38ef0,
title = "Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features",
abstract = "We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36{\%} for CDH1, 35{\%} for RASSF1A and APC, 29{\%} for CDH13, 16{\%} for FHIT, 15{\%} for RARβ, 11{\%} for GSTP1, 7{\%} for p16INK4A, 4{\%} for DAPK, and 2{\%} for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.",
author = "R. Maruyama and Shinichi Toyooka and Toyooka, {K. O.} and K. Harada and Virmani, {A. K.} and S. Z{\"o}chbauer-M{\"u}ller and Farinas, {A. J.} and F. Vakar-Lopez and Minna, {J. D.} and A. Sagalowsky and B. Czerniak and Gazdar, {A. F.}",
year = "2001",
month = "12",
day = "15",
language = "English",
volume = "61",
pages = "8659--8663",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features

AU - Maruyama, R.

AU - Toyooka, Shinichi

AU - Toyooka, K. O.

AU - Harada, K.

AU - Virmani, A. K.

AU - Zöchbauer-Müller, S.

AU - Farinas, A. J.

AU - Vakar-Lopez, F.

AU - Minna, J. D.

AU - Sagalowsky, A.

AU - Czerniak, B.

AU - Gazdar, A. F.

PY - 2001/12/15

Y1 - 2001/12/15

N2 - We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARβ, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.

AB - We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARβ, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035893756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035893756&partnerID=8YFLogxK

M3 - Article

C2 - 11751381

AN - SCOPUS:0035893756

VL - 61

SP - 8659

EP - 8663

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -